Novavax | NVAX - Selling And Administration Expenses


Novavax reported $25.53M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Adma Biologics USD 20.19M 2.86M Dec/2025
Agenus USD 10.56M 13.04M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Cassava Sciences USD 6.66M 1.24M Dec/2025
Geron USD 41.67M 2.67M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
MannKind USD 29.09M 2.53M Sep/2025
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 308M 40M Dec/2025
Novartis USD 3.44B 132M Dec/2025
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025